**Plasmodium vivax Seroprevalence in Bred Cynomolgus Monkeys, China**

To the Editor: Malaria caused by *Plasmodium* spp. is one of the most prevalent parasitic diseases in the world, especially in tropical countries. *P. vivax* represents the second most prevalent of malaria species. Therefore, as measures to control the high death rates in humans caused by *P. falciparum* become more effective, *P. vivax* is likely to become the primary malaria threat (1). In *P. vivax* infection, the main clinical signs and symptoms are fever, chills, nausea and vomiting, generalized body pain and fatigue, toxic shock and pulmonary edema, retinal hemorrhage, renal failure, uremic encephalopathy, and thrombocytopenia (2–6).

Because of their phylogenetic proximity to humans, nonhuman primates have been used extensively as animal models of human diseases (7). Thousands of workers come in contact with monkeys, but little information about the prevalence of *P. vivax* in bred cynomolgus monkeys (Macaca fascicularis) is available worldwide. The objective of our investigation was to examine whether *P. vivax* seroprevalence is present in bred cynomolgus monkeys in the People’s Republic of China.

A total of 328 blood samples were collected by venous puncture during June 2008–September 2009. Of these, 224 blood samples were from 4 nonhuman primate centers in Guangxi Zhuang Nationality Autonomous Region and 108 blood samples were from 2 nonhuman primate centers in Guangdong Province. All of the cynomolgus monkeys were caged. Each cage has 2 rooms, 1 indoors and 1 outdoors. The monkeys spend ≈10 hours in the indoor room each day during the daytime. The age and sex of monkeys are listed in the Table. Serum samples were separated and stored at −20°C before testing.

Serum samples were tested for *P. vivax* antibodies by using a commercially available ELISA kit (Tiancheng Yiliu Co., Ltd, Shanghai, China), according to the manufacturer’s instructions. This kit uses biotinylated anti-*P. vivax* as a coating antigen and is specifically for monkeys. Positive and negative control serum samples were provided in the kit and included in each test. Those samples with doubtful results were retested.

Differences in the seroprevalence of *P. vivax* in bred cynomolgus monkeys according to sex and area were analyzed by using the χ² test in SPSS 13.0 standard version for Windows (SPSS Inc., Chicago, IL, USA). The differences were considered to be statistically significant when the p value obtained was <0.05.

The total prevalence of anti-*P. vivax* antibodies in bred cynomolgus monkeys in southern China was 3.4% (11/328), which was lower than the prevalence of anti-*P. vivax* antibodies in captured monkeys (*Alouatta seniculus*, *Saguinus midas*, and *Pithecia pithecia*) in French Guiana (8). The prevalence in female monkeys (3.1%, 5/161) was slightly lower than that in male monkeys (3.6%, 6/167); the seroprevalence of 3.6% (8/224) in Guangxi Zhuang Nationality Autonomous Region was slightly higher than that in Guangdong Province (2.9%, 3/104) (Table), but these differences were not significant (p>0.05). A total of 52 monkey serum samples from nonhuman primate center E in Guangdong Province were found seronegative for *P. vivax* antibodies (Table). The difference in prevalence of *P. vivax* antibodies in different nonhuman primate centers may be related to differences in ecologic and geographic conditions, climate conditions, as well as in the management practices. All of the nonhuman primate centers are surrounded by hills or paddy fields, and the environment is favorable for *Anopheles* mosquitoes. The mosquito control measures, including the use of antimosquito insecticides and good drainage facilities for preventing water collection on the ground, were better executed at nonhuman primate center E than at the other nonhuman primate centers.

### Table. Prevalence of *Plasmodium vivax* antibodies in serum samples, from bred cynomolgus monkeys in southern China, determined by ELISA, 2008–2009*

| Province center | Female | | Male | | Total |
|----------------|--------|----------------|--------|----------------|----------|
|                |        | Age, y | No. positive/ no. examined | Prevalence, % | Age, y | No. positive/ no. examined | Prevalence, % | No. positive/ no. examined | Prevalence, % |
| GX             |        |        |                        |               |        |                        |               |                          |               |
| A              | 3.0–5.0 | 0/20  | 0                      | 3.0–6.5       | 1/30    | 3.3                     |               | 1/50                      | 2               |
| B              | 3.0–5.0 | 0/29  | 0                      | 3.0–5.5       | 1/33    | 3.0                     |               | 1/62                      | 1.6              |
| C              | 3.0–5.0 | 1/27  | 3.7                    | 3.0–5.5       | 2/33    | 6.1                     |               | 3/60                      | 5               |
| D              | 2.0–5.0 | 2/31  | 6.5                    | 3.0–5.0       | 1/21    | 4.8                     |               | 3/52                      | 5.8              |
| Subtotal       | 2.0–5.0 | 3/107 | 2.8                    | 3.0–6.5       | 5/117   | 4.3                     |               | 8/224                     | 3.6              |
| GD             |        |        |                        |               |        |                        |               |                          |               |
| E              | 2.5–3.0 | 0/14  | 0                      | 2.5–3.0       | 0/13    | 0                       |               | 0/27                      | 0               |
| F              | 7.0–8.0 | 0/12  | 0                      | 8.0–9.0       | 0/13    | 0                       |               | 0/25                      | 0               |
| Subtotal       | 2.5–8.0 | 2/54  | 3.7                    | 2.5–9.0       | 1/50    | 2                       |               | 3/104                     | 2.9              |
| Total          |        | 4/167 | 3.1                    |               | 6/167   | 3.6                     |               | 11/328                    | 3.4              |

*GX, Guangxi Zhuang Nationality Autonomous Region; GD, Guangdong Province; –, not applicable.*
Our survey showed *P. vivax* seropositivity in 5 of the 6 nonhuman primate centers in southern China, which is a potential health problem for bred cynomolgus monkeys. This finding also indicates the risk for infection with *P. vivax* for the employees of these nonhuman primate centers. Therefore, studies are warranted that assess the seroprevalence of *P. vivax* infection in persons who work in these nonhuman primate centers, as well as the seroprevalence of *P. vivax* infection in wild monkeys.

This work is supported in part by grants from the National Basic Research Program (973 program) of China (grant no. 2007CB513104), the State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences (SKLVEB2009FKT014 and SKLVEB2010FKT010), and the Specialized Research Fund for the Doctoral Program of Higher Education (Grant no. 20094404120016).

Hai-Long Li, Zhen-Yong Liu, Juan Li, Lin Ai, Dong-Hui Zhou, Zi-Guo Yuan, Rui-Qing Lin, Ya-Biao Weng, and Xing-Quan Zhu

Author affiliations: State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, CAAS, Lanzhou, China (H.-L. Li, Z.-Y. Liu, J. Li, J. Ai, X.-Q. Zhu); and South China Agricultural University, Guangzhou, China (H.-L. Li, J. Li, L. Ai, D.-H. Zhou, Z.-G. Yuan, R.-Q. Lin, Y.-B. Weng)

DOI: 10.3201/eid1705.101846

References

1. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of *Plasmodium vivax* malaria. Am J Trop Med Hyg. 2001;64:97–106.
2. Karahocagil MK, Baran AI, Yaman G, Cicek M, Bilici A, Binici I, et al. Case report: two *Plasmodium vivax* malaria cases in the Van Province [in Turkish]. Türkiye Parazitol Derg. 2009;33:172–3.
3. Song JY, Park CW, Jo YM, Kim JY, Kim JH, Yoon HJ, et al. Two cases of *Plasmodium vivax* malaria with the clinical picture resembling toxic shock. Am J Trop Med Hyg. 2007;77:609–11.
4. Lee JH, Chin HS, Chung MH, Moon YS. Retinal hemorrhage in *Plasmodium vivax* malaria. Am J Trop Med Hyg. 2010;82:219–22. doi:10.4269/ajtmh.2010.09-0439
5. Das BS. Renal failure in malaria. J Vector Borne Dis. 2008;45:83–97.
6. Kaur D, Wasir Y, Gulati S, Bagga A. Unusual presentation of *Plasmodium vivax* malaria with severe thrombocytopenia and acute renal failure. J Trop Pediatr. 2007;53:210–2. doi:10.1093/troped/ fnm092
7. Carlsson HE, Schapiro SJ, Farah I, Hau J. Use of primates in research: a global overview. Am J Primatol. 2004;63:225–37. doi:10.1002/ajp.20054
8. Volney B, Pouliquen JF, De Thoisy B, Fandeur T. A sero-epidemiological study of malaria in human and monkey populations in French Guiana. Acta Trop. 2002;82:11–23. doi:10.1016/S0001-706X (02)00036-0

Address for correspondence: Xing-Quan Zhu, Department of Parasitology, State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, CAAS, 1 Xujiaping, Yanchangbu, Lanzhou, Gansu Province 730046, People’s Republic of China; email: xingquanzhu1@hotmail.com

**Imported Dengue Virus Serotype 3, Yemen to Italy, 2010**

To the Editor: Dengue is a mosquito-transmitted viral disease endemic to the tropics and subtropics worldwide. It is caused by 4 dengue virus serotypes (DENV-1–4) that belong to the genus Flavivirus. The disease varies from dengue fever to life-threatening hemorrhagic fever and shock that are associated with secondary infections. During recent decades, dengue incidence and prevalence have increased in disease-endemic areas, and the disease has been increasingly recognized in travelers (1). We report a case of dengue in a man who had traveled to Yemen.

In June 2010, a 38-year-old Italian man was admitted to the hospital for high fever (maximum 39.5°C) after a 1-week work-related stay in Yemen, near Mukalla, in the province of Hadhramaut. The patient had visited the countryside where he was heavily bitten by mosquitoes.

On the third day after onset of fever, the patient started to experience strong and unremitting frontal and retro-orbital headache and joint pains, which lasted for 5 days. He also experienced vomiting. Laboratory test results showed mild leukopenia (2.41 × 10³ cells/mm³) and lowered platelet counts (96 × 10³ cells/mm³), increased liver alanine aminotransferase levels (151 U/L), and mildly abnormal blood clotting (prothrombin time, international normalized ratio 1.24). In 1 week, the patient started to recover and was discharged from the hospital. The patient received antimicrobial (levoxacin) and antipyretic (acetaminophen) drugs. Laboratory testing after discharge showed increased levels of hepatic enzymes, which reached maximum levels on day 13 after onset of symptoms (alanine aminotransferase 669 U/L) and decreased to within reference limits in 1 month.

A plasma sample taken on day 6 after disease onset was positive for flavivirus RNA by reverse transcription–PCR (RT-PCR) specific for members of the genus Flavivirus (2). The RT-PCR product was sequenced, and according to BLAST (www.ncbi.nlm.nih.gov/blast), the 184-bp sequence obtained shared 99% nt identity with dengue serotype 3 viruses in GenBank. The plasma sample also had positive results for dengue virus nonstructural protein 1.